KEY DETAILS
CNBC reports that in an analysis of roughly 2,300 women with obesity or who are overweight, CagriSema was associated with 25% weight loss on average at 68 weeks compared with 3% with placebo.
Newstalkzb.co.nz reports that a Rabobank report found GLP-1 weight-loss medications were accelerating demand for protein, with United States surveys suggesting nearly one in eight adults has used a GLP-1 medication for weight loss in recent years.
Nzherald.co.nz reports that Corkran expected these conditions to continue for two to three years, noting rising input costs and volatility were also expected to remain.
Finance.yahoo.com reports that Zepbound captured nearly 60% of total prescriptions in the U.S. branded obesity market by the end of the second quarter.
Medicaldaily.com reports that Houston RX LLC began recalling 64 vials of compounded tirzepatide with niacinamide on September 25 because of a lack of assurance of sterility.
CNBC reports that in an analysis of roughly 2,300 women with obesity or who are overweight, CagriSema was associated with 25% weight loss on average at 68 weeks compared with 3% with placebo. That is the headline, but the news covered more than one analysis. Finance.yahoo.com reports that Zepbound captured nearly 60% of total prescriptions in the U.S. branded obesity market by the end of the second quarter. There is more below.
CNBC reports that Novo said on Tuesday, October 20, that CagriSema showed 25% weight loss on average among adult women in a new analysis conducted after a late-stage trial. CNBC reports that in an analysis of roughly 2,300 women with obesity or who are overweight, CagriSema was associated with 25% weight loss on average at 68 weeks compared with 3% with placebo. CNBC reports that CagriSema, a combination of semaglutide and another drug called cagrilintide that targets the amylin pathway, is expected to launch early next year.
Newstalkzb.co.nz reports that a Rabobank report found GLP-1 weight-loss medications were accelerating demand for protein, with United States surveys suggesting nearly one in eight adults has used a GLP-1 medication for weight loss in recent years. Newstalkzb.co.nz reports that the same report found tight global beef and sheepmeat supply will mean positive prices in the near term, but longer-term value will depend on market diversification, customer relationships and reliable delivery.
Nzherald.co.nz reports that Corkran expected these conditions to continue for two to three years, noting rising input costs and volatility were also expected to remain. Next, prescription and sales figures from Eli Lilly.
Finance.yahoo.com reports that Zepbound captured nearly 60% of total prescriptions in the U.S. branded obesity market by the end of the second quarter, while Mounjaro continued to gain ground in the U.S. type 2 diabetes market. Finance.yahoo.com reports that the two drugs generated $27.7 billion in combined sales in the first half of 2026, up approximately 88% year over year and accounting for about 65% of Eli Lilly's total revenues. Finance.yahoo.com reports that investors will closely monitor that performance when Lilly reports third-quarter results on October 29, 2026. Not every GLP-1 headline was about growth.
Medicaldaily.com reports that Houston RX LLC later recalled 64 vials of compounded tirzepatide with niacinamide because of a lack of assurance of sterility. Medicaldaily.com reports that an August inspection produced a Form 483 listing 14 observations, including exposed skin during sterile work, reversed cleanroom air pressure, microbial growth in a clean hood, unsterilized equipment, possible mold near the cleanroom, and research-grade ingredients. Medicaldaily.com reports that, according to FDA enforcement records summarized in the nonprofit MedShadow Foundation's roundup of recent compounded GLP-1 drug recalls, Houston RX began recalling 64 two-milliliter vials of tirzepatide-niacinamide 20 mg/2 mg per mL on September 25. That recall is specific to one pharmacy's compounded product.
You can find the full analysis write-up at CNBC, the Rabobank report coverage at Newstalkzb.co.nz and Nzherald.co.nz, the Eli Lilly prescription numbers at Finance.yahoo.com, and the recall details at Medicaldaily.com. Each outlet carries more detail than fits into this summary.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.